{"entity":{"id":"sitneprotafib","kind":"drug","name":"Sitneprotafib","aka":[],"tldr":"Sitneprotafib is an experimental small-molecule drug from Allist Pharmaceuticals in phase 3 trials for non-small-cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma, with its target not yet stated publicly.","summary":"Sitneprotafib (JAB-3312) is a small-molecule drug developed by Allist Pharmaceuticals. The sponsor describes its target as SHP2, which OnCo does not yet have a target page for. The sponsor states: JAB-3312 (sitneprotafib) is a second-generation allosteric SHP2 inhibitor developed by Jacobio, described as having more potent anti-tumour activity than earlier SHP2 inhibitors; combined with the KRAS G12C inhibitor glecirasib (JAB-21822) in a registrational phase 3 trial for first-line KRAS G12C-mutated NSCLC. ClinicalTrials.gov describes the intervention as: JAB-3312 administered orally as a tablet or capsule. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06416410 (JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation), in non-small-cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma. The largest, NCT06416410, plans to enrol 392 participants with primary completion expected 2029-09-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Sitneprotafib","url":"https://clinicaltrials.gov/search?intr=Sitneprotafib"},{"label":"Sponsor pipeline page","url":"https://www.jacobiopharma.com/en/pipeline/"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","colorectal","pancreatic"],"sections":[],"technologies":[],"targets":["shp2"],"drugs":[],"companies":["allist"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06416410","nct05288205"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"JAB-3312","modality":"small molecule","mechanism":"JAB-3312 (sitneprotafib) is a second-generation allosteric SHP2 inhibitor developed by Jacobio, described as having more potent anti-tumour activity than earlier SHP2 inhibitors; combined with the KRAS G12C inhibitor glecirasib (JAB-21822) in a registrational phase 3 trial for first-line KRAS G12C-mutated NSCLC.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/sitneprotafib/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"shp2","kind":"target","name":"SHP2 (PTPN11)","route":"/targets/shp2/"}],"company":[{"id":"allist","kind":"company","name":"Shanghai Allist Pharmaceuticals","route":"/companies/allist/"}],"trial":[{"id":"nct06416410","kind":"trial","name":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation","route":"/trials/nct06416410/"},{"id":"nct05288205","kind":"trial","name":"Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation","route":"/trials/nct05288205/"}]}}